Biotricity, Inc. (BTCY)
OTCMKTS · Delayed Price · Currency is USD
0.5400
-0.0300 (-5.26%)
Aug 29, 2025, 3:34 PM EDT
Biotricity Revenue
Biotricity had revenue of $3.87M in the quarter ending June 30, 2025, with 21.00% growth. This brings the company's revenue in the last twelve months to $14.46M, up 18.12% year-over-year. In the fiscal year ending March 31, 2025, Biotricity had annual revenue of $13.79M with 14.32% growth.
Revenue (ttm)
14.46M
Revenue Growth
+18.12%
P/S Ratio
1.00
Revenue / Employee
314.40K
Employees
46
Market Cap
14.43M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 13.79M | 1.73M | 14.32% |
Mar 31, 2024 | 12.06M | 2.42M | 25.15% |
Mar 31, 2023 | 9.64M | 1.99M | 26.00% |
Mar 31, 2022 | 7.65M | 4.27M | 126.02% |
Mar 31, 2021 | 3.38M | 1.97M | 138.75% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
Biotricity News
- 18 days ago - Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins - GlobeNewsWire
- 20 days ago - Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th - GlobeNewsWire
- 27 days ago - BTCY: CA: A Fun Idea With Yield But Risky - Seeking Alpha
- 6 weeks ago - Biotricity, Inc. (BTCY) Q4 2025 Earnings Conference Call Transcript - Seeking Alpha
- 6 weeks ago - Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach - GlobeNewsWire
- 6 weeks ago - Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th - GlobeNewsWire
- 5 months ago - Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed - GlobeNewsWire
- 6 months ago - Biotricity expands intellectual property portfolio with 14 new patents - Seeking Alpha